This report provides an insight into life sciences M&A deal activity in 2022 and supplements our 2023 global M&A intelligence report, which is now in its ninth edition.
The life sciences sector is broad and captures a number of sub-sectors, including pharmaceutical, medical devices and biotech.
The report looks at a selection of our international corporate life sciences transactions to identify trends and developments, which can provide insightful intelligence for those operating in the sector and considering M&A activity, both domestically or internationally.
The report focuses on five key themes:
Marco de Morpurgo, Global Co-Chair and EU Regulatory Lead – Life Sciences
Please note, requests will be reviewed and approved at the discretion of DLA Piper. We cannot guarantee you will receive the report after submitting a request. Alternatively, please get in touch with your usual DLA Piper contact to request a copy.
Unsolicited e-mails and information sent to DLA Piper or the independent DLA Piper Relationship firms will not be considered confidential, may be disclosed to others, may not receive a response, and do not create a lawyer-client relationship with DLA Piper or any of the DLA Piper Relationship firms. Please do not include any confidential information in this message. Also, please note that our lawyers do not seek to practice law in any jurisdiction in which they are not properly permitted to do so.